And some of our concentration goes up even higher than that. So we’ll have more data on that topic coming out this year. But we’re hoping that 235, owing to it’s really good potency, really good drug exposures after QD administration, as Brian Skorney mentioned, we’ve got very nice multiples at either of our doses against the Omicron variant. And then you add on top of that, the potential of having good tissue uptake where the virus might be hiding out, a little harder to treat. So we’re hoping that, that could all add up to having some impact on rebound and we will certainly be looking at that in our study, because we’ll be dosing for five days and then we have a 28-day follow-up. So we’ll have a chance to watch these people out to Day 3. So that’s an intriguing hypothesis that we’ll be testing.
The other question that you had, I think, was about RSV. We have 938 obviously advancing in three high-risk patient trials right now. We have 323 proceeding nicely in a Phase 1 study, it will be ready to look at in virally-infected people, hopefully, soon enough. And you asked, I think the specific question on how could you look at that as a combination. And one of the possibilities that could be thought about is doing that in a challenge study. We already have a fantastic challenge study data with 938. One could do a challenge study with 323 and also look at the combination of the two to see what parameters one might be able to improve. So you asked what would be the earliest way that you could look at that. That is probably the earliest, quickest way to get interesting data about combinations.
Eric Joseph: Okay. Great. Great. I appreciate you taking my question. Thanks.
Jay Luly : Thank you.
Operator: Thank you. And I show our next question comes from the line of Roanna Ruiz from SVB Securities. Please go ahead.
Roanna Ruiz: Great. Thanks. Afternoon everyone. So a quick question on the SPRINT trial. I was curious on the clinical symptoms secondary analysis. Specifically, are you going to focus in on a key set of symptoms similar to what we saw with Shionogi’s late-stage trial data, or will you plan to be a bit more broad in your exploration of different symptoms of COVID?
Jay Luly : Tara, do you want to handle that?
Tara Kieffer : Sure. Hi, Roanna, it’s Tara. So we’ll certainly look at all the symptoms in our trial, and then we’ll have the ability to do analysis of specific subsets. So to your point, looking at those five symptoms that Shionogi was able to show an effect on. So we’ll be able to do both, and we’ll also be able to learn this way with the comprehensive data set, how best to move into later studies as well.
Roanna Ruiz: Got it. Makes sense. And
Tara Kieffer : Dose it help?
Roanna Ruiz: Yes, that helps. And for — I want to ask about 938 for the RSVHR study, do you expect to see a good balance of different high-risk patients being enrolled like across COPD, asthma, et cetera? And I’m not sure if I missed this, but do you have any input on what you think the sequence of readouts might be between your different RSV trials, like RSVPEDs, RSVTx and RSV HR?
Jay Luly: Yeah. So the readouts on those will just need more data through season of RSV to really tell. There are such different patient populations, PEDs, there’s — just three very different patient populations. And so I think we just need more information to know what we’ll pull ahead. With regards to your question about, are we worried about too much enrichment of one patient population or another? Is that what you asked? I mean, for example, we are capping those older age 65 and asthma at 20%. This will help enrich for the more high-risk COPD and congestive heart failure patients. So it won’t be just completely filled up with asthmatics if that is what you’re getting at in your question. Is that helpful?
